Imagine a simple test that costs a little but saves lives—and actually pays for itself five times over. That is exactly what researchers at National Taiwan University Hospital have found with Helicobacter pylori screening, a stool-based test that could become a powerful new tool in the global fight against gastric cancer.
Gastric cancer remains one of the world's deadliest cancers, but Taiwan's research team has developed a prevention model that turns the economics of public health on its head. Their 10-year randomized clinical trial, published in JAMA, demonstrated that pairing an H. pylori stool antigen test (HPSA) with existing colorectal cancer screening is not just medically sound—it is genuinely cost-saving. For every unit of currency invested in H. pylori screening, approximately five units return in prevented treatment costs and improved health outcomes.
"To translate the findings of this pragmatic randomized clinical trial into public health policy, cost considerations are essential," said Dr. Yi-Chia Lee, professor of internal medicine in the Division of Gastroenterology and Hepatology at National Taiwan University and first author of the study. Her team built a Markov decision-analytic model to estimate 30 years of cost-effectiveness, showing that the investment upfront pays dividends in lives saved and expensive cancer treatments avoided.
The strategy works by catching and eradicating H. pylori bacteria—a known cause of stomach inflammation and cancer—before it progresses to deadly tumors. While initial costs cover screening and antibiotic treatment, the downstream savings are substantial: fewer surgeries, chemotherapy sessions, and targeted therapies, not to mention the immeasurable value of quality time with family instead of time in treatment.
What makes this finding especially hopeful is its portability. The research team collaborated with European and U.S. researchers to test the model under higher health care cost settings, and the screening remained cost-effective even in those expensive markets. In an accompanying editorial, John M. Inadomi, deputy editor of JAMA, confirmed that countries with gastric cancer incidence similar to or higher than Taiwan could expect comparable economic benefits, assuming costs, antibiotic resistance, and reinfection rates follow similar patterns.
The implications stretch far beyond Taiwan. Gastric cancer disproportionately affects populations in East Asia, Eastern Europe, and Latin America. If nations adopt this integrated screening approach—adding HPSA testing to existing fecal immunochemical tests already used for colorectal cancer—they could simultaneously tackle two cancers with one patient visit. The JAMA publication of these findings on June 1, 2026, marks a moment when a simple stool test transitioned from promising research to a policy recommendation with hard numbers behind it.